Stenzl A - Search Results

1

Herrmann J, Kaufmann S, Zhang C, Rausch S, Bedke J, Stenzl A, Nikolaou K, Kruck S, Seith F. Herrmann J, et al. Among authors: stenzl a. Urologe A. 2022 Apr;61(4):428-440. doi: 10.1007/s00120-022-01806-7. Epub 2022 Apr 7. Urologe A. 2022. PMID: 35389061 German.

2

[The interdisciplinary approach to improve treatment quality of prostate cancer. Optimized nerve sparing in radical prostatectomy].

Sievert KD, Anastasiadis AG, Hennenlotter J, Schilling D, Merseburger AS, Nagele U, Lichy MP, Schlemmer HP, Ulmer A, Vogel U, Sotlar K, Kuczyk M, Stenzl A. Sievert KD, et al. Among authors: stenzl a. Urologe A. 2007 Sep;46(9):1104-12. doi: 10.1007/s00120-007-1445-z. Urologe A. 2007. PMID: 17701393 German.

3

[Use of a gelatine-thrombin matrix for closure of the access tract without a nephrostomy tube in minimally invasive percutaneous nephrolitholapaxy].

Schilling D, Winter B, Merseburger AS, Anastasiadis AG, Walcher U, Stenzl A, Nagele U. Schilling D, et al. Among authors: stenzl a. Urologe A. 2008 May;47(5):601-7. doi: 10.1007/s00120-008-1673-x. Urologe A. 2008. PMID: 18311555 German.

4

[Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?].

Schilling D, Küfer R, Kruck S, Stenzl A, Kuczyk MA, Merseburger AS. Schilling D, et al. Among authors: stenzl a. Urologe A. 2008 Oct;47(10):1334-8. doi: 10.1007/s00120-008-1781-7. Urologe A. 2008. PMID: 18566791 German.

5

Activation of PI3K is associated with reduced survival in renal cell carcinoma.

Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA. Merseburger AS, et al. Among authors: stenzl a. Urol Int. 2008;80(4):372-7. doi: 10.1159/000132694. Epub 2008 Jun 27. Urol Int. 2008. PMID: 18587247

6

[Diagnostic procedures in upper urinary tract urothelial carcinoma].

Patschan O, Horstmann M, Thomas C, Schlemmer HP, Stenzl A. Patschan O, et al. Among authors: stenzl a. Urologe A. 2008 Nov;47(11):1487-96. doi: 10.1007/s00120-008-1893-0. Urologe A. 2008. PMID: 19011832 German.

7

[Secondary hormonal ablation in hormone-independent prostate cancer].

Schilling D, Gakis G, Bökeler U, Stenzl A, Kuczyk MA, Merseburger AS. Schilling D, et al. Among authors: stenzl a. Urologe A. 2009 Feb;48(2):183-8; quiz 189-90. doi: 10.1007/s00120-009-1940-5. Urologe A. 2009. PMID: 19214617 Review. German.

8

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.

Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, Stenzl A. Feyerabend S, et al. Among authors: stenzl a. Prostate. 2009 Jun 15;69(9):917-27. doi: 10.1002/pros.20941. Prostate. 2009. PMID: 19267352 Clinical Trial.

9

Economic aspects of bladder cancer: what are the benefits and costs?

Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A. Sievert KD, et al. Among authors: stenzl a. World J Urol. 2009 Jun;27(3):295-300. doi: 10.1007/s00345-009-0395-z. Epub 2009 Mar 7. World J Urol. 2009. PMID: 19271220 Free PMC article. Review.

10

Should photodynamic diagnosis be standard practice for bladder cancer?

Stenzl A, Kruck S. Stenzl A, et al. Expert Rev Anticancer Ther. 2009 Jun;9(6):697-9. doi: 10.1586/era.09.46. Expert Rev Anticancer Ther. 2009. PMID: 19496705 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

838 results

Search Page